Evotec AG and Second Genome decided to collaborate in small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases. The collaboration comprises the identification and optimisation of novel compounds as well as licence agreements for already existing assets developed by Evotec. Second Genome’s unique approach to identify and modulate microbiome-mediated pathways will be further enhanced by the use and the results of Evotec’s integrated drug discovery platform.

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. The company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer’s disease.

Second Genome has built a novel platform for microbiome drug discovery and is engaged in active programmes in multiple areas of significant unmet medical need.

ADVERTISEMENT

As part of the collaboration, the team will work together to screen microbiome-mediated targets of interest identified by the Second Genome microbiome discovery platform with Evotec’s technology platform, chemical libraries and other pre-clinical capabilities. The agreement between Evotec and Second Genome triggers an undisclosed upfront payment. Evotec is also eligible for pre-clinical, clinical and regulatory milestones as well as royalty payments related to commercialisation.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are pleased to contribute to Second Genome’s unique approach to treat microbiome-mediated diseases in the body with a particular emphasis on the gut. The enrichment and maturation of Second Genome’s project portfolio through our contributions will enhance the Company’s clinical pipeline in the near future.”

Previous post

Samsung Bioepis Submits a Biosimilar Candidate, to the European Medicines Agency

Next post

Against Being Against GMOs: The Golden Rice Story

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.